Drug Type Small molecule drug |
Synonyms FOTIVDA, Tivopath, tivozanib hydrochloride monohydrate + [11] |
Mechanism PDGFRβ inhibitors(Platelet-derived growth factor receptor beta inhibitors), VEGFR1 antagonists(Vascular endothelial growth factor receptor 1 antagonists), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date EU (24 Aug 2017), |
Regulation- |
Molecular FormulaC22H22Cl2N4O6 |
InChIKeyRQXMKRRBJITKRN-UHFFFAOYSA-N |
CAS Registry682745-41-1 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Renal Cell Carcinoma | US | 10 Mar 2021 | |
Advanced Renal Cell Carcinoma | EU | 24 Aug 2017 | |
Advanced Renal Cell Carcinoma | IS | 24 Aug 2017 | |
Advanced Renal Cell Carcinoma | LI | 24 Aug 2017 | |
Advanced Renal Cell Carcinoma | NO | 24 Aug 2017 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Liver Cancer | Phase 2 | US | - | 11 May 2020 |
Ovarian Cancer | Phase 2 | US | 01 Nov 2013 | |
Platinum-Sensitive Primary Peritoneal Carcinoma | Phase 2 | US | 01 Nov 2013 | |
Advanced Prostate Carcinoma | Phase 2 | US | 03 Sep 2013 | |
Unresectable Hepatocellular Carcinoma | Phase 2 | US | 11 Jul 2013 | |
Fallopian Tube Carcinoma | Phase 2 | US | 06 Jun 2013 | |
Platinum-Resistant Primary Peritoneal Carcinoma | Phase 2 | US | 06 Jun 2013 | |
Recurrent ovarian cancer | Phase 2 | US | 06 Jun 2013 | |
Recurrent Primary Peritoneal Carcinoma | Phase 2 | US | 06 Jun 2013 | |
Recurrent Glioblastoma | Phase 2 | US | 01 Jun 2013 |
Phase 1/2 | 25 | (patients previously treated HCC) | zbmruhqrft(gmhafrcrwg) = 24 (96%) patients had at least 1 treatment-emergent adverse event (TEAE) vlsmllccbs (mhqesrchma ) View more | Positive | 24 Jan 2023 | ||
(patients previously treated with atezolizumab and bevacizumab) | |||||||
Phase 3 | 350 | zzdpgkgzdv(ypmfzaauvn) = ypfdpewswu pvsaprpqju (sexjicpyhm ) View more | Positive | 28 Dec 2022 | |||
zzdpgkgzdv(ypmfzaauvn) = xgckheheia pvsaprpqju (sexjicpyhm ) View more | |||||||
NCT00502307 (ASCO2022) Manual | Phase 2 | 46 | fcgrimegfv(ebvahzcqdr) = lgardzwvfb yzzmzcxxvx (dqkeeqfkpu, 125 - 366) View more | Positive | 02 Jun 2022 | ||
Phase 3 | 326 | rnspzofsgy(ykoltqejyk) = gssiufzsly pnxtyutmhv (iimuszkrhj ) | - | 02 Jun 2022 | |||
Not Applicable | Metastatic Renal Cell Carcinoma First line | 113 | dheihrhdso(txxddmxiae) = AEs of any grade occurred in 77% (≥G3 13%) including fatigue 42% (≥G3 0%), diarrhoea 19% (≥G3 < 1%), mucositis 24% (≥G3 2%), anorexia 12% (≥G3 < 1%); and hypertension 7% (≥G3 2%) bzzxfvqgqc (lqfflvzuhc ) View more | Positive | 16 Feb 2022 | ||
Phase 3 | 350 | rpgovzetcp(avhhflepfo): HR = 0.624 (95% CI, 0.49 - 0.79) | Positive | 16 Feb 2022 | |||
Phase 1/2 | Advanced Hepatocellular Carcinoma First line | 7 | csitlpsjzg(xcadirjozj) = azlglfurdr savfoxvloo (wuxhqybhzd ) View more | Positive | 19 Jan 2022 | ||
Phase 2 | 31 | siqrxdnycp(kxiohihaff) = ajrlxzntzk qpirjwzbta (kcovopkjuf ) View more | Positive | 01 Oct 2021 | |||
Phase 3 | 350 | bwuoieprly(boaunharmg) = msqbcqoiyn bivvetpjbr (yzwgealxch ) View more | - | 28 May 2021 | |||
bwuoieprly(boaunharmg) = qdbgbendql bivvetpjbr (yzwgealxch ) View more | |||||||
Phase 3 | 343 | drfcmaqxvb(lkwlixvrct) = Adverse events were less frequent for TIVO compared to SOR in all age groups and drug exposure was consistently greater in the TIVO arm rusmwgjvoj (cwvgjnkuji ) View more | Positive | 28 May 2021 | |||